Robert Knoerl is an instructor in medicine at the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston. Contact author:
Am J Nurs. 2021 Apr 1;121(4):26-30. doi: 10.1097/01.NAJ.0000742060.56042.e7.
Chemotherapy-induced peripheral neuropathy (CIPN) occurs in more than 68% of patients receiving the neurotoxic chemotherapy agents commonly used to treat breast, gastrointestinal, gynecologic, and hematologic malignancies. CIPN, often experienced initially as numbness, tingling, or pain in the upper or lower extremities, may progress to the point where the resultant decline in physical function requires a reduction in the chemotherapy dose. This article provides nurses with strategies to use in assessing, managing, and educating patients who are at risk for or who are already experiencing CIPN. Currently, the American Society of Clinical Oncology endorses only one treatment for CIPN: duloxetine 60 mg/day. Discussing CIPN with patients before chemotherapy is initiated and throughout the course of treatment promotes its early identification and management, which may minimize its impact on physical function and chemotherapy dosing, reducing the patient's risk of experiencing chronic symptoms after chemotherapy ends.
化疗引起的周围神经病（CIPN）发生在接受常用于治疗乳腺癌、胃肠道癌、妇科癌和血液系统恶性肿瘤的神经毒性化疗药物的患者中超过 68%。CIPN 通常最初表现为上肢或下肢麻木、刺痛或疼痛，可能进展到导致身体功能下降的程度，需要减少化疗剂量。本文为护士提供了用于评估、管理和教育有发生 CIPN 风险或已经患有 CIPN 的患者的策略。目前，美国临床肿瘤学会仅推荐一种治疗 CIPN 的药物：度洛西汀 60mg/天。在开始化疗前和整个治疗过程中与患者讨论 CIPN，可以促进其早期识别和管理，从而最大程度地减少其对身体功能和化疗剂量的影响，降低患者在化疗结束后出现慢性症状的风险。
